Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262

de Wit, M., Honecker, F., Wedding, U., Waldenmaier, D., Dorn, J., Warm, M., Al-Batran, S., Schmidt, M., Kreienberg, R., Jaeger, E., Saupe, S., Mueller, L., Burkhard, J. O. and Harbeck, N. (2010). Correlation Comprehensive Geriatric Assessment (CGA) and Inflammation and Nutrition Parameters with Outcome Measures in the Phase III PELICAN Trial for Metastatic Breast Cancer (MBC). Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

This list was generated on Thu Apr 18 13:41:30 2024 CEST.